華仁藥業(300110.SZ):擬收購裕源藥業、浦北新科各100%股權
格隆匯 6 月 23日丨華仁藥業(300110.SZ)公佈,公司於2020年6月23日召開第六屆董事會第二十次(臨時)會議,審議通過了《關於收購廣西裕源藥業有限公司100%股權、浦北縣新科藥品包裝有限公司100%股權的議案》(“裕源藥業”、“浦北新科”),同意公司以自有資金收購自然人阮傳明、阮瑩樂、何慧所持有廣西裕源藥業有限公司100%股權、浦北縣新科藥品包裝有限公司100%股權。
同日,公司與阮傳明、阮瑩樂、何慧在青島簽署《關於廣西裕源藥業有限公司100%股權、浦北縣新科藥品包裝有限公司100%股權的股權收購框架協議》。
裕源藥業成立於1997年3月,位於廣西欽州市浦北縣城工業區,註冊資本4,940萬元,經營範圍為大容量注射劑的生產、銷售;多層共擠膜輸液用袋、聚丙烯輸液瓶、易折式塑料輸液容器用聚丙烯組合蓋、直立式聚丙烯輸液袋的生產、使用。裕源藥業是專業大輸液生產企業,現有塑瓶、直立軟袋和玻瓶大輸液生產線共9條,擁有各類輸液品規40餘個,產品包括調節水電解質及酸鹼平衡類、抗菌消炎類、心腦血管類及胃腸疾病類等多個藥品類別,具備年生產大輸液6億瓶(袋)的規模。產品銷售覆蓋廣西地區及周邊省市,經歷二十多年發展,在大輸液領域形成了較大優勢。
浦北縣新科藥品包裝有限公司為廣西裕源藥業有限公司關聯企業,成立於2006年6月,經營範圍為:塑料包裝製品(不含印刷品)加工、銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.